110 YEARS. 110 STORIES. 110 REASONS TO RAISE AWARENESS FOR GBS. [CONSHOHOCKEN, PA] — May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl. Distinguished as a unique condition,…
Misunderstanding Plasma Donation Has Real Consequences for Patients by Jacob Fuller When Richard Sperry received a devastating diagnosis in late 2019, he began planning out the last days of his life. He, his wife, and his three daughters were grappling with the grief and uncertainty of his condition. All of that changed after an appointment…
GBS|CIDP Awareness Month This May! 110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS and CIDP. This May, join us in recognizing a major milestone in our community, the 110th anniversary of Guillain-Barré syndrome (GBS). This will be celebrated during GBS|CIDP Awareness Month by listening to stories and sharing them to help raise much-needed…
Kedrion’s 10% IVIG study ABOUT THE KB071 STUDY The KB071 Study is testing the safety and clinical benefit of a new intravenous immunoglobulin (IVIg) therapy to see what, if any, benefit it may have on your condition. After screening, eligible participants will gradually reduce their pre-study CIDP medication for up to 12 weeks (this is…
Join us for a refresher in the basics for GBS and CIDP; we will cover the diagnosis, treatment, and long-term outcomes for both conditions through a conversation with Dr. Ken Gorson, a former chair of the Foundation’s Global Medical Advisory Board. This webinar will be for educational purposes only and will not be troubleshooting individual…
The FORWARD STUDY The FORWARD STUDY is an open-label study in North America and Europe. The study has been reviewed and approved for ethics and safety. All patients will receive Tanruprubart. The purpose of this study is to better understand Tanruprubart’s effects by collecting information such as: What is Tanruprubart? Tanruprubart (ANX005) is an investigational…
Your Voice Matters- Take part in our research! RTI Health Solutions (RTI-HS), a non-profit research organization, to recruit adults to participate in a focus group. You and fellow participants will be asked about your experiences with chronic inflammatory demyelinating polyneuropathy (CIDP) and your opinions about CIDP treatments. If you have been diagnosed with CIDP, you…
Emnergize CIDP Clinical Trial The Emnergize study is designed to evaluate how the investigational study drug* may work (also known as efficacy) and how safe it is for the use in adults living with CIDP. This study will evaluate the clinical study drug compared to a placebo. *The investigational study drug, empasiprubart, is not approved…
Sharing news as we wrap up our MMN awareness month regarding the research of Professor Simon Rinaldi and Dr. Nicolas Dubuisson, and celebrating a major new $600,000 grant, the Foundation is honored to have helped support their progress in their fight against inflammatory neuropathies. Learn more here.
The AMPLIFI CIDP clinical study The AMPLIFI study is evaluating the safety and effectiveness of a new investigational drug called IMVT-1402, administered as weekly subcutaneous (SC) injections using an autoinjector in people with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Why is this clinical study being done? Antibodies are molecules in the blood that are produced to…
In recognition of February as MMN Awareness Month, join us for an MMN Ask the Experts webinar focused on Multifocal Motor Neuropathy (MMN). This session will provide an overview of MMN, including diagnosis, treatment options, and emerging research. Featured speakers include Dr. Chafic Karam, neurologist and member of the Foundation’s Global Medical Advisory Board, and…
The Emvigorate study is designed to evaluate how the investigational study drug* may work (also known as efficacy) and how safe it is for the use in adults living with CIDP. This study will evaluate the investigational study drug compared to the current standard-of-care intravenous immunoglobulin (IVIg). *The investigational study drug, empasiprubart, is not approved…
At GBS|CIDP Foundation International, we recognize the power of unity and awareness in the fight against rare diseases. On Rare Disease Day, we stand with our global community to shine a light on Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and related neuropathies. This day is a vital reminder that…
In 1993, Clive Phillips stood at the bottom of the Col du Télégraphe, a mountain pass in the French Alps, watching the world’s top cyclists tackle the climb during the Tour de France. Some 30 years and a Multifocal Motor Neuropathy (MMN) diagnosis later, Clive found himself back in the same spot. This time, he was…
Meet our new Program Manager, Sandra Bermudez Join us in welcoming Sandra Bermudez to the Foundation team! Driven by a deep passion for helping others live fuller and more joyful lives, Sandra Bermúdez is a Psychologist, Health Coach, MBSR-certified practitioner, and a member of the International Association for Health Coaches. She gently guides individuals in developing…
Pagination
Spotlight
